STOK
HealthcareStoke Therapeutics, Inc. · Biotechnology · $2B
What is Stoke Therapeutics, Inc.?
Stoke Therapeutics is an early-stage biopharmaceutical company focused on developing antisense oligonucleotide medicines that target the root causes of severe genetic diseases. Headquartered in Bedford, Massachusetts, the company is working to bring precision RNA-based therapies to patients with rare neurological conditions.
Stoke Therapeutics uses its proprietary TANGO platform — Targeted Augmentation of Nuclear Gene Output — to design antisense oligonucleotides that precisely upregulate protein expression in cells. Rather than silencing genes, the platform is built to boost them, addressing genetic diseases caused by insufficient protein production. The company's lead program targets Dravet syndrome, a severe genetic epilepsy, while a second program is in preclinical development for autosomal dominant optic atrophy. A collaboration with Acadia Pharmaceuticals expands its pipeline into rare neurodevelopmental diseases.
Stoke Therapeutics was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
- STK-001: Phase I/IIa clinical candidate for Dravet syndrome
- STK-002: Preclinical program for autosomal dominant optic atrophy
- TANGO platform for RNA upregulation via antisense oligonucleotides
- Collaboration with Acadia Pharmaceuticals for CNS rare disease medicines
Is STOK a Good Stock to Buy?
UQS Score rates STOK as Below Average overall, reflecting the realities of an early-stage clinical-stage biotech.
The Growth pillar stands out as the relative bright spot in STOK's profile, consistent with a company advancing clinical programs and expanding its pipeline through partnerships. Risk is rated Neutral, suggesting the company's risk profile is neither unusually alarming nor particularly reassuring relative to sector peers.
Both the Quality and Moat pillars are rated Weak, which is typical for pre-revenue biotechs without established products or durable competitive advantages. Valuation is rated Elevated, meaning the market is pricing in significant future success.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does STOK pay dividends?
No — Stoke Therapeutics, Inc. does not currently pay a dividend.
Stoke Therapeutics does not pay a dividend, which is standard for early-stage biopharmaceutical companies. Available capital is directed toward clinical development, platform research, and pipeline expansion rather than shareholder distributions. Investors in STOK are generally seeking long-term value from potential drug approvals rather than income.
When does STOK report earnings?
Stoke Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, Stoke does not yet generate product revenue, so quarterly reports focus on pipeline progress, cash runway, and research and development spending. Key milestones to watch include clinical trial updates for STK-001 and collaboration developments with Acadia Pharmaceuticals.
For the most recent quarter's results and management commentary, visit Stoke Therapeutics' investor relations page directly.
STOK Price History
-10.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Stoke Therapeutics, Inc.?
Based on Stoke Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
STOK Long-term Outlook
Stoke's fundamental outlook is shaped by its clinical pipeline rather than commercial performance. The Good Growth pillar rating reflects meaningful pipeline advancement potential, particularly as STK-001 progresses through clinical trials for Dravet syndrome. However, the Elevated Valuation pillar and Weak Quality pillar signal that the current market price embeds optimistic assumptions that carry execution risk. The path to value creation runs through clinical readouts and, ultimately, regulatory approval.
Growth drivers
- Advancement of STK-001 through clinical trials for Dravet syndrome
- Expansion of the TANGO platform into additional rare genetic diseases
- Revenue and milestone potential from the Acadia Pharmaceuticals collaboration
Key risks
- Clinical trial failure or delays could significantly impair the investment thesis
- Elevated valuation leaves limited margin of safety if pipeline progress disappoints
- Pre-revenue status means continued dependence on capital markets for funding
STOK vs Peers
Stoke Therapeutics operates in the rare disease and genetic medicine space alongside a range of clinical-stage and specialty biotech peers.
Day One focuses on pediatric cancers rather than genetic epilepsy, targeting a different rare disease niche with its own clinical pipeline.
Adaptive Biotechnologies applies its immune medicine platform to oncology and infectious disease, using a distinct technology approach from Stoke's RNA-upregulation strategy.
Immunome pursues antibody-based therapies for cancer and inflammatory diseases, representing a different modality and therapeutic focus than Stoke's ASO platform.
Frequently Asked Questions
What does Stoke Therapeutics do?
Stoke Therapeutics develops antisense oligonucleotide medicines designed to treat the underlying causes of severe genetic diseases. Its proprietary TANGO platform works by upregulating protein expression — boosting genes rather than silencing them. The lead program targets Dravet syndrome, a severe genetic epilepsy, and a collaboration with Acadia Pharmaceuticals extends the platform into rare CNS diseases.
Does STOK pay dividends?
No, Stoke Therapeutics does not pay a dividend. As a clinical-stage biopharmaceutical company with no approved products, the company reinvests all available capital into research, clinical trials, and pipeline development. Dividend payments are not typical for companies at this stage of development.
When does STOK report earnings?
Stoke Therapeutics reports financial results on a quarterly basis, as is standard for US-listed public companies. Because it is pre-revenue, reports center on pipeline updates, cash position, and R&D expenditure. For the most current earnings schedule, check Stoke Therapeutics' investor relations page.
Is STOK a good stock to buy?
UQS Score rates STOK as Below Average overall. The Growth pillar is rated Good, reflecting pipeline momentum, but Quality and Moat are both Weak — common for pre-revenue biotechs. Valuation is Elevated, meaning the stock prices in considerable future success. Whether that risk-reward fits your portfolio depends on your own investment criteria.
Is STOK overvalued?
The UQS Valuation pillar for STOK is rated Elevated, indicating the market is assigning a premium price relative to the company's current fundamentals. For a clinical-stage biotech, this often reflects investor expectations for pipeline success rather than existing revenues. The full valuation breakdown is available to UQS Pro members.
How does STOK compare to its competitors?
Stoke Therapeutics occupies a distinct niche with its RNA-upregulation TANGO platform and focus on genetic epilepsy. Peers like Day One Biopharmaceuticals, Adaptive Biotechnologies, and Immunome each pursue different therapeutic areas and technology modalities. UQS Pro members can view side-by-side pillar comparisons across these companies.
What is STOK's market cap bracket?
Stoke Therapeutics is classified as a mid-cap company based on its current market capitalization. Within the biotech sector, mid-cap clinical-stage companies like STOK typically carry meaningful pipeline risk but also significant upside potential if clinical programs succeed.
Who founded Stoke Therapeutics?
Stoke Therapeutics was originally incorporated as ASOthera Pharmaceuticals, Inc. in 2014 before rebranding to its current name in May 2016. Founding and leadership details are publicly available on the company's website and in SEC filings.
Is STOK a long-term quality investment?
As a long-term quality indicator, UQS rates STOK as Below Average, driven by Weak Quality and Moat scores that reflect its pre-revenue, clinical-stage status. Long-term quality potential depends heavily on whether STK-001 and other pipeline candidates achieve regulatory approval. The Growth pillar offers some optimism, but execution risk remains high.
What is the main competitive advantage of Stoke Therapeutics?
Stoke's primary differentiator is its TANGO platform, which is designed to upregulate — rather than silence — gene expression using antisense oligonucleotides. This approach addresses a class of genetic diseases caused by insufficient protein production, a mechanism that few other platforms directly target. However, the UQS Moat pillar is currently rated Weak, reflecting the early-stage nature of this advantage.
What sector does STOK belong to?
Stoke Therapeutics operates in the Healthcare sector, specifically within the biopharmaceutical and rare disease subsegment. It focuses on genetic medicines using RNA-based technology, placing it alongside other clinical-stage genetic therapy companies rather than commercial-stage pharmaceutical firms.
Is STOK a growth stock or value stock?
Based on UQS pillar labels, STOK leans toward the growth category — the Growth pillar is rated Good, reflecting pipeline expansion and clinical advancement. However, the Elevated Valuation pillar means investors are already paying a premium for that growth potential, which reduces the margin of safety typically associated with value investing.
Unlock Full STOK Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare STOK side-by-side with sector peers
- ✓Screen for quality stocks across the Healthcare sector
- ✓Get the full analyst view available to Pro members
Pro Analysis
STOK — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 25, 2026 | 38.3 | 16.7 | 29.0 | 62.5 | 67.3 | 28.5 | +2.9 |
| May 7, 2026 | 35.4 | 21.5 | 29.0 | 62.5 | 47.1 | 21.5 | -0.1 |
| May 3, 2026 | 35.5 | 21.5 | 29.0 | 62.5 | 47.1 | 22.0 | +0.4 |
| Apr 26, 2026 | 35.1 | 21.5 | 29.0 | 62.5 | 47.1 | 19.5 | +1.4 |
| Apr 19, 2026 | 33.7 | 21.5 | 29.0 | 62.5 | 47.1 | 10.0 | -0.9 |
| Apr 14, 2026 | 34.6 | 21.5 | 29.0 | 62.5 | 47.1 | 16.5 | -0.3 |
| Apr 12, 2026 | 34.9 | 21.5 | 29.0 | 62.5 | 47.1 | 18.5 | -0.7 |
| Apr 5, 2026 | 35.6 | 21.5 | 29.0 | 62.5 | 47.1 | 23.0 | +0.1 |
| Apr 2, 2026 | 35.5 | 21.5 | 29.0 | 62.5 | 47.1 | 22.5 | — |
STOK — Pillar Breakdown
Quality
— 16.7/100 (25%)Stoke Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.5/100 (20%)Stoke Therapeutics, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 67.3/100 (15%)Stoke Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 28.5/100 (15%)Stoke Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
How many years of FCF the market cap represents.
Moat
— 29/100 (25%)Stoke Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for STOK.
Score Composition
Financial Data
More Stock Analysis
How is the STOK UQS Score Calculated?
The UQS (Unified Quality Score) for Stoke Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Stoke Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Stoke Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.